Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.71 |
| ▸ | FLT3 | P36888 | 2/20 | 0.71 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.71 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.71 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | FER | P16591 | 1/20 | 0.71 |
| ▸ | CDK2 | P24941 | 1/20 | 0.71 |
| ▸ | MARK3 | P27448 | 1/20 | 0.71 |
| ▸ | FLT4 | P35916 | 1/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.71 |
| ▸ | CLK2 | P49760 | 1/20 | 0.71 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.71 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.71 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.71 |
| ▸ | STK3 | Q13188 | 1/20 | 0.71 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.71 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215112 | 0.87 | MAP2K4 (0.61) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL29549117 | 0.87 | MAP2K4 (0.61) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL4316858 | 0.83 | DCLK1 (1.00) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL2731639 | 0.83 | FLT3 (0.75) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL16025493 | 0.81 | FLT3 (0.62) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL13503113 | 0.80 | FLT3 (0.54) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL2469031 | 0.80 | AXL (0.55) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL5374591 | 0.80 | MAP2K4 (0.71) | CSNK1DMAP2K4NTRK1MAPK1MAPK6 | |
| SCHEMBL4332948 | 0.80 | MAP2K4 (0.49) | CSNK1DFLT3CLK4DCLK1PRKD3 | |
| SCHEMBL30415837 | 0.80 | MAP2K4 (0.49) | CSNK1DFLT3CLK4DCLK1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3986886-A2 | SUBSTITUTED PYRROLIDINE AMIDES V | Grünenthal GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254552-A2 | SUBSTITUTED PYRROLIDINE AMIDES V | Grünenthal GmbH (DE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3728233-A1 | SUBSTITUTED PYRROLIDINE AMIDES II | Grünenthal GmbH (DE) | 2020-10-28 | — | — | EP | disclosed |
| WO-2008079073-A1 | INDAZOLYL SULPHONAMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | WO | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| EP-1618093-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SINGNAL PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004094388-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | CSNK1D 349/4885FLT3 2753/4885CLK4 1126/4885 |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 164/4885FLT3 1374/4885CLK4 1032/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | CSNK1D 1173/4885FLT3 177/4885CLK4 662/4885 |
| US-20050107457-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 245/4885FLT3 1130/4885CLK4 865/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | CSNK1D 164/4885FLT3 1374/4885CLK4 1032/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | CSNK1D 410/4885FLT3 114/4885CLK4 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.